Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05166460
Other study ID # 1026704
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 1, 2023
Est. completion date January 15, 2026

Study information

Verified date April 2023
Source Nova Scotia Health Authority
Contact Thomas Skinner
Phone 902-425-3940
Email tomaaskinner@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Avoiding warm ischemia time during vascular anastomosis of the renal allograft is important to prevent damage. The investigators are studying a cooling device that may control the temperature of the renal allograft during transplant surgery; attempting to keep temperatures at or below 5°C for at least 60 minutes. If found effective, this could eliminate warm ischemia and potentially prevent damage to transplanted kidneys.


Description:

Warm ischemia can damage a renal allograft in many different ways often leading to early failure of the kidney transplant and sometimes even death of the transplant recipient. For this reason every effort is made to keep the allograft cold during the removal and transportation, and protocols have been developed to ensure this. Although kidneys are kept below 5°C during transportation, they re-warm rapidly during the transplant surgery. On average, kidneys are exposed to 40 or more minutes of dangerously warm temperatures during transplant surgery. To avoid damage, it is important to reduce the amount of time it is exposed to warm temperatures. Currently, there are no devices or standardized protocols available to ensure a kidney stays cold during the transplant surgery. The Principal Investigator has developed Kidney Skinn, a device that may control the temperature of the renal allograft during transplant surgery; keeping allograft temperatures at or below 5°C for at least 60 minutes. If found effective, this could eliminate warm ischemia and potentially prevent damage to transplanted kidneys. The device may also potentially provide retraction and support for the kidney during the transplant operation, making the surgery easier to perform. Additionally, the device may be found to be easily removed once the transplant is complete. A previous study was conducted with the Kidney Skinn in animals; the next step is to investigate whether the device can perform in the human clinical setting. This study will be done in 2 steps. Part A: a series of consecutive consenting patients to determine device initial safety, and Part B: a single-centre randomized-controlled pilot study of kidney transplant recipients.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 45
Est. completion date January 15, 2026
Est. primary completion date January 15, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. =18 years of age at time of transplant 2. Slated to receive a single cadaveric organ 3. Donor declared by traditional neurological determination of death (NDD) 4. Standard criteria donor (SCD) or Extended criteria donor (ECD) 5. Consent obtained prior to the transplant operation Exclusion Criteria: 1. Living donor (LD) 2. Donor after cardiocirculatory death (DCD) 3. Highly sensitized patients (those with Panel-reactive antibody or PRA >80%) 4. Recipient of a previous kidney transplant

Study Design


Intervention

Device:
Kidney cooling device
renal cooling device designed to maintain renal hypothermia at or below 5ºC for 60 minutes.

Locations

Country Name City State
Canada Queen Elizabeth II Health Sciences Centre Halifax Nova Scotia

Sponsors (2)

Lead Sponsor Collaborator
Thomas Skinner Nova Scotia Health Authority

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part A: Device design is deemed suitable to move into the traditional feasibility stage (Part B of protocol) The Kidney Skinn cooling device can be utilized during vascular anastomosis, and the ability of the device to maintain surface and core temperatures of transplant kidneys at <5ºC for the duration of the vascular anastomosis. 6 months
Primary Part B: To determine the feasibility of a trial using the Kidney Skinn cooling device to usual care to ameliorate warm ischemia time during kidney transplantation Feasibility Outcomes will include the following:
Ability to randomize >60% of eligible patients
>75% of patients randomized to the Kidney Skinn arm use the device
70% of patients randomized to the device (Kidney Skinn) achieve a renal allograft surface temperature of <5C for the duration of the vascular anastomosis.
2 years
Secondary Proportion of patients who develop delayed graft function (need for dialysis in the first week after transplantation) compared with usual care Delayed Graft function as defined by the need for dialysis in the first 7 post operative days 7 days
Secondary Difference in ischemia-reperfusion injury biomarker levels between the intervention and control groups Urine and serum biomarkers for ischemia-reperfusion injury will be collected at specific key time points pre and post transplantation on all Part B trial participants. Specifically, urine and serum samples for unique markers of kidney injury (KIM-1 & NGAL), inflammation (TNFR1, MCP-1) and fibrosis (suPAR, YKL 40). 7 days
Secondary Serum creatinine level at discharge from initial hospitalization for transplantation Local laboratory serum creatinine drawn per standard of care on all renal transplant recipients on day of discharge 5-7 days
Secondary Differences in achieved renal allograft surface temperature comparing the Kidney Skinn (intervention arm) versus usual care (control arm) For each surgery, K-type 30 gauge thermocouples (each less than 0.25mm in external diameter) will be used in the renal allograft at a depth of 5 mm and 15 mm. This will be to measure surface (cortical) and core (medullary) temperatures, respectively. 60 minutes
See also
  Status Clinical Trial Phase
Completed NCT04369456 - Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients N/A
Recruiting NCT06001320 - De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip Early Phase 1
Withdrawn NCT04560582 - Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Not yet recruiting NCT05782543 - Renal Ex Vivo Warm Advanced Resuscitation Through Machine Perfusion N/A
Completed NCT03996551 - ExeRTiOn2- The Weight Gain Prevention Exercise in Renal Transplant Online Study N/A
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Recruiting NCT04508907 - A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients Phase 4
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Recruiting NCT04713774 - Bone Density and Vascular Calcifications Evolution After Renal Transplant
Active, not recruiting NCT05483725 - Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
Recruiting NCT06095492 - Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus N/A
Active, not recruiting NCT04207177 - Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects Phase 4
Recruiting NCT03410654 - Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR. Early Phase 1
Completed NCT03373266 - Serun Fluoride and Kidney Transplant Phase 2
Completed NCT04835948 - Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
Not yet recruiting NCT04514666 - VOCs in Kidney and Liver Transplants N/A
Recruiting NCT03373500 - Effect of Dietary Salt Reduction on Blood Pressure in Kidney Transplant Recipients N/A
Recruiting NCT05900401 - Delayed Tolerance Through Mixed Chimerism Phase 1/Phase 2
Recruiting NCT05977387 - Pediatric Kidney Transplant
Terminated NCT05747053 - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients